Cytarabine and daunorubicin liposomal (Vyxeos)
Revision as of 15:24, 10 June 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. ==Preliminary data== <!-- Pre...")
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio.
Preliminary data
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. link to original article PubMed